Daratumumab in multiple myeloma
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The development of effective monoclonal antibodies for the treatment of myeloma has been a long journey of clinical and drug development. Identification of the right target antigen was a critical part of the process. CD38 as a target has been considered for some time, but clinically, daratumumab, a CD38 monoclonal antibody, was the first to be tested, and it has delivered the best clinical responses as a single agent to date. Its proven safety and efficacy in combination with other antimyeloma agents have led to several US Food and Drug Administration approvals for treating myeloma. Furthermore, the results of early trials in the induction therapy setting have demonstrated a beneficial role when it is added to the existing induction regimens. This review summarizes the importance of CD38 as a target and examines the clinical development of the CD38 monoclonal antibody daratumumab and its clinical significance in combination regimens in both patients with relapsed/refractory myeloma and patients with newly diagnosed myeloma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Functions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943 · cited 1×
“NK cells are effector lymphocytes that play a key role in the functioning of innate immunity and provide protection against malignancies and other pathogens.(36) NK cell depletion or defects in NK cell activity increased susceptibility to viral infections in mice,(37) and NK cell depletion can potentially have deleter…”
BackgroundDaratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · cited 1×
“Patients with a potentially higher risk of respiratory complications received post-infusion medications, which consisted of diphenhydramine on the first and second days after all infusions, a short-acting β2-adrenergic receptor agonist, and a long-acting bronchodilator such as tiotropium or salmeterol.(15) Given the h…”
BackgroundCarfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332 · cited 1×
“5 months (similar to the findings for the other control arms in this setting).(26,27) The 30-month PFS rates were 58% and”
ResultElotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322 · cited 1×
“5 months (similar to the findings for the other control arms in this setting).(26,27) The 30-month PFS rates were 58% and”
ResultSelf-citationTargeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · cited 5×
“On the basis of the findings in this study, an effective dose of daratumumab was determined to be 16 mg/kg.(11) The preliminary efficacy of daratumumab was further confirmed in the open-label, multicenter, phase 2 trial SIRIUS, which included patients who were treated with 3 or more prior lines of therapy (including a…”
BackgroundMethodInfluentialLonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854 · cited 3×
“The preliminary efficacy of daratumumab was further confirmed in the open-label, multicenter, phase 2 trial SIRIUS, which included patients who were treated with 3 or more prior lines of therapy (including a PI and an IMiD) or were double-refractory (refractory to both PI and IMiDs).(12) In part 1 of the study, patien…”
MethodSelf-citationOverdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521 · cited 2×
“Macrophages efficiently engulfed daratumumab-coated tumor cells, and this suggests that ADCP is an effective antitumor mechanism of daratumumab.(7) In addition to these immune-mediated mechanisms, daratumumab may also have an immunomodulatory role by depleting CD38+ immune regulatory cells and promoting T-cell expansi…”
BackgroundKumar, S. K., Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., Hillengass, J., Leleu, X., Beksac, M., Alsina, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.138 · Cited by 351 · cited 1×
“On the basis of the encouraging activity among double-refractory patients, with a known median overall survival (OS) of 13 months, the use of monoclonal antibodies was rapidly moved to earlier lines of therapy.(2) The results were deeper and more sustained responses with good tolerability.”
BackgroundResolving the daratumumab interference with blood compatibility testing
Chapuy, C. I., Nicholson, R. T., Aguad, M. D., Chapuy, B., Laubach, J. P., Richardson, P. G., Doshi, P., & Kaufman, R. M. (2015) · Transfusion · doi:10.1111/trf.13069 · Cited by 239
Nijhof, I. S., Groen, R. W. J., Noort, W. A., van Kessel, B., de Jong-Korlaar, R., Bakker, J., van Bueren, J. J. L., Parren, P. W. H. I., Lokhorst, H. M., van de Donk, N. W. C. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1813 · Cited by 151
Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2018) · Blood · doi:10.1182/blood-2018-120737 · Cited by 50
Cited by
The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape
de Jong, M. M. E., Kellermayer, Z., Papazian, N., Tahri, S., Hofste op Bruinink, D., Hoogenboezem, R., Sanders, M. A., van de Woestijne, P. C., Bos, P. K., Khandanpour, C., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00931-3 · Cited by 250
Lu, Q., Yang, D., Li, H., Zhu, Z., Zhang, Z., Chen, Y., Yang, N., Li, J., Wang, Z., Niu, T., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216660 · Cited by 15
Metadata
- Authors
- Nooka, A. K., Kaufman, J. L., Hofmeister, C. C., Joseph, N. S., Heffner, T. L., Gupta, V. A., Sullivan, H. C., Neish, A. S., Dhodapkar, M. V., & Lonial, S.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2019-04-05
- Volume
- 125
- Issue
- 14
- Pages
- 2364-2382
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2929340554
- Cited by
- 162
- References
- 12
- FWCI
- 11.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.